John L. Berk, MD

Associate Professor, Medicine

John Berk
617.358.4774
72 E. Concord St Housman (R)

Biography

Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.

Other Positions

  • Member, Pulmonary Center, Boston University
  • Assistant Director, Amyloidosis Center, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University

Education

  • Case Western Reserve University, MD
  • Wesleyan University, BA

Publications

  • Published on 4/28/2020

    Brannagan TH, Wang AK, Coelho T, Waddington Cruz M, Polydefkis MJ, Dyck PJ, Plante-Bordeneuve V, Berk JL, Barroso F, Merlini G, Conceição I, Hughes SG, Kwoh J, Jung SW, Guthrie S, Pollock M, Benson MD, Gertz M. Early Data on Long-Term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis: A 2-Year Update From the Open-Label Extension of the NEURO-TTR Trial. Eur J Neurol. 2020 Apr 28. PMID: 32343462.

    Read at: PubMed
  • Published on 3/4/2020

    Obici L, Berk JL, González-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT, Wang JJ, Adams D. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020 Mar 04; 1-10. PMID: 32131641.

    Read at: PubMed
  • Published on 3/1/2020

    González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D. Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol. 2020 Mar; 267(3):713-714. PMID: 32030522.

    Read at: PubMed
  • Published on 12/18/2019

    Coelho T, Yarlas A, Waddington-Cruz M, White MK, Sikora Kessler A, Lovley A, Pollock M, Guthrie S, Ackermann EJ, Hughes SG, Karam C, Khella S, Gertz M, Merlini G, Obici L, Schmidt HH, Polydefkis M, Dyck PJB, Brannagan Iii TH, Conceição I, Benson MD, Berk JL. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. J Neurol. 2020 Apr; 267(4):1070-1079. PMID: 31853709.

    Read at: PubMed
  • Published on 12/5/2019

    Khor YM, Cuddy S, Harms HJ, Kijewski MF, Park MA, Robertson M, Hyun H, Di Carli MF, Bianchi G, Landau H, Yee A, Sanchorawala V, Ruberg FL, Liao R, Berk J, Falk RH, Dorbala S. Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. Eur J Nucl Med Mol Imaging. 2019 Dec 05. PMID: 31807884.

    Read at: PubMed
  • Published on 12/2/2019

    Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. J Card Fail. 2019 Dec 02. PMID: 31805416.

    Read at: PubMed
  • Published on 11/14/2019

    González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol. 2020 Mar; 267(3):703-712. PMID: 31728713.

    Read at: PubMed
  • Published on 10/22/2019

    Kaku M, Berk JL. Neuropathy Associated with Systemic Amyloidosis. Semin Neurol. 2019 10; 39(5):578-588. PMID: 31639841.

    Read at: PubMed
  • Published on 1/22/2019

    Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019 01 22; 139(4):431-443. PMID: 30586695.

    Read at: PubMed
  • Published on 1/1/2019

    Berk JL. TTR Gene Silencers for Hereditary ATTR Amyloidosis: More than ICER Recognized. J Manag Care Spec Pharm. 2019 Jan; 25(1):15-16. PMID: 30589634.

    Read at: PubMed

View 84 more publications: View full profile at BUMC

View all profiles